The San Diego, CA-based company is facing a fine because of closing the Grail acquisition without waiting for EU antitrust approval, according to a Reuters report.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,